On the fence about getting a COVID-19 vaccine boost shot?
This might help.
Pfizer and its German partner BioNtech said results from a late-stage clinical trial demonstrated a 95.6 percent efficacy rate of guarding against the virus, including the highly-virulent Delta variant.
The trial results released Thursday were based on a study of 10,000 participants 16-years old and older.
Among those who got the booster shot - only five came down with COVID-19, compared to the placebo group which saw 109 cases of the disease.
The vaccine makers said the median time between the second dose and the booster shot or the placebo in the study was around 11 months.
The two companies say they will submit data from the trial to the FDA, The European Medicines Agency, and other regulatory agencies as soon as possible.
Booster shots from the Pfizer-BioNTech vaccine and the Moderna vaccine have both been approved in the U.S. and Europe for older populations and for those who are immuno-compromised.
The FDA has also given the green light on an extra shot of the one-dose Johnson and Johnson vaccine...
and said Americans can choose a different shot from their original inoculation as a booster.